Welcome to our dedicated page for Marsh & Mclennan news (Ticker: MMC), a resource for investors and traders seeking the latest updates and insights on Marsh & Mclennan stock.
Marsh & McLennan (NYSE: MMC) is a global leader in professional services specializing in risk management, insurance brokerage, and strategic consulting. This dedicated news hub provides investors and industry professionals with verified updates directly from the company and authoritative third-party analysis.
Access comprehensive collection of earnings reports, strategic initiatives, and leadership updates alongside expert commentary on MMC's market position. Our curated feed simplifies tracking regulatory developments and industry trends impacting this Fortune 500 firm.
Key coverage areas: quarterly financial disclosures, mergers & acquisitions activity, corporate governance changes, and recognition within insurance/consulting sectors. All content undergoes strict verification to ensure compliance with financial reporting standards.
Bookmark this page for real-time updates on MMC's global operations across 130+ countries. Monitor critical developments in risk solutions through Marsh, reinsurance advisory via Guy Carpenter, and consulting services from Mercer/Oliver Wyman through one centralized source.
Huron has finalized the divestiture of its life sciences commercial and R&D strategy business to Oliver Wyman, part of Marsh McLennan (NYSE: MMC). This strategic move allows Huron to focus more on enhancing its industry expertise in healthcare and education, alongside advancing its technology capabilities across all segments. The transaction is expected to streamline operations, directing resources towards core business areas, thereby aiming for improved client service and operational efficiency.
Oliver Wyman, a consulting firm within Marsh McLennan (NYSE: MMC), has acquired Huron's life sciences strategy consulting practice. The deal enhances Oliver Wyman's capabilities in healthcare, allowing for comprehensive solutions to complex industry challenges. With this acquisition, Oliver Wyman adds 80 skilled professionals, including 12 partners, expanding its talent pool and client relationships within the pharmaceutical and biotechnology sectors. This strategic move aims to strengthen Oliver Wyman's leadership in life sciences consulting and broaden its service offerings.
Oliver Wyman introduces the Holistic Market Model, a comprehensive analysis framework for the US stock market, celebrating Marsh McLennan's 150th anniversary. Developed by former managing partner Jacques Cesar, this model examines 150 years of market dynamics, addressing drivers such as inflation and interest rates. It aims to surpass traditional models like CAPM and CAPE. Key findings indicate that pre-pandemic equity valuations were elevated but not extreme, while corporate profit margins are at a 100-year high.
Marsh McLennan (NYSE: MMC) reported strong third quarter 2021 results, with GAAP revenue rising 16% to $4.6 billion and underlying revenue up 13%. Operating income surged 37% to $740 million, while adjusted EPS increased 32% to $1.08. For the first nine months of 2021, consolidated revenue was $14.7 billion, marking a 15% increase. The Risk & Insurance Services segment generated $2.7 billion in revenue (+17%) and Consulting reached $1.9 billion (+13%). The company repurchased 1.9 million shares for $300 million in Q3.
Marsh McLennan (NYSE: MMC) announced the launch of its Cyber Risk Analytics Center, aimed at consolidating cyber risk data and analytics across its divisions: Marsh, Guy Carpenter, Mercer, and Oliver Wyman. This center will provide clients with insights into their cyber threats and risk management strategies. With the increasing prevalence of cyberattacks leading to significant financial losses, the center is designed to enhance clients' resilience to cyber risks. Managing Director Scott Stransky will lead the initiative, supported by collaboration with academic and governmental partners.
FAQ
What is the current stock price of Marsh & Mclennan (MMC)?
What is the market cap of Marsh & Mclennan (MMC)?
